HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Stephens, A. W. Articles by Hirs, C. H. Search for Related Content PubMed PubMed Citation Articles by Stephens, A. W. Articles by Hirs, C. H. Social Bookmarking                      What's this?

J. Biol. Chem., Vol. 262, Issue 3, 1044-1048, 01, 1987

Antithrombin-III Denver, a reactive site variant

AW Stephens, BS Thalley and CH Hirs

Antithrombin-III Denver is a mutant protein which differs from the normal in being defective in serine protease binding (Sambrano, J. E., Jacobson, L. J., Reeve, E. B., Manco-Johnson, M. J., and Hathaway, W. E. (1986) J. Clin. Invest. 77, 887-893). It was isolated from the blood of an individual heterozygous for the abnormal gene by: affinity separation on heparin-Sepharose to obtain an antithrombin fraction, and gel filtration of the species present following complexing of the antithrombin fraction with a small excess of thrombin. The reduced, S- carboxymethylated protein formed a mixture of soluble tryptic peptides which was fractionated on Vydac C18. A single, unique peptide not present in a parallel experiment with normal antithrombin-III was isolated. This peptide was identified by sequence analysis and synthesis to correspond to residues 394-399 in the known sequence of the inhibitor, with leucine replacing reactive site P'1 residue Ser394. Although chromatograms of the tryptic peptides from the normal and mutant proteins were otherwise indistinguishable, the existence of additional residue replacements is not excluded. Measurements of the rate of thrombin binding by the mutant protein with p-aminobenzamidine as a fluorescent indicator showed that the second-order rate constant is reduced drastically. Meaningful measurements with the mutant protein could only be made in the presence of heparin and revealed a reduction of about 4000-fold in the rate constant.
CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				R. Morenweiser, E. A. Auerswald, A. van de Locht, H. Fritz, J. Sturzebecher, and M. T. Stubbs Structure-based Design of a Potent Chimeric Thrombin Inhibitor J. Biol. Chem., August 8, 1997; 272(32): 19938 - 19942. [Abstract] [Full Text] [PDF]

				S. T. Olson, A. W. Stephens, C. H. W. Hirs, P. E. Bock, and I. Björk Kinetic Characterization of the Proteinase Binding Defect in a Reactive Site Variant of the Serpin, Antithrombin J. Biol. Chem., April 28, 1995; 270(17): 9717 - 9724. [Abstract] [Full Text] [PDF]

				M. J. Mulligan-Kehoe, R. Wagner, C. Wieland, and R. Powell A Truncated Plasminogen Activator Inhibitor-1 Protein Induces and Inhibits Angiostatin (Kringles 1-3), a Plasminogen Cleavage Product J. Biol. Chem., March 9, 2001; 276(11): 8588 - 8596. [Abstract] [Full Text] [PDF]